COVID-19 Impact on Global Hematologic Malignancies Market Size, Status and Forecast 2020-2026

September 2020 | 96 pages | ID: C8A150B569B9EN
QYResearch

Abstracts

This report focuses on the global Hematologic Malignancies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hematologic Malignancies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Pfizer, Inc.
• F. Hoffmann-LA Roche ltd
• Sanofi-Aventis
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Novartis AG
• GlaxoSmithKline PLC
• Celgene Corporation
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company limited

Market segment by Type, the product can be split into

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

Market segment by Application, split into

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Hematologic Malignancies status, future forecast, growth opportunity, key market and key players.
• To present the Hematologic Malignancies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Hematologic Malignancies are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hematologic Malignancies Revenue
1.4 Market Analysis by Type
  1.4.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Leukemia
  1.4.3 Lymphoma
  1.4.4 Multiple Myeloma
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
  1.5.2 Chemotherapy
  1.5.3 Radiotherapy
  1.5.4 Immunotherapy
  1.5.5 Stem Cell Transplantation
  1.5.6 Others
1.6 Coronavirus Disease 2019 (Covid-19): Hematologic Malignancies Industry Impact
  1.6.1 How the Covid-19 is Affecting the Hematologic Malignancies Industry
    1.6.1.1 Hematologic Malignancies Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Hematologic Malignancies Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Hematologic Malignancies Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Hematologic Malignancies Market Perspective (2015-2026)
2.2 Hematologic Malignancies Growth Trends by Regions
  2.2.1 Hematologic Malignancies Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Hematologic Malignancies Historic Market Share by Regions (2015-2020)
  2.2.3 Hematologic Malignancies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Hematologic Malignancies Market Growth Strategy
  2.3.6 Primary Interviews with Key Hematologic Malignancies Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Hematologic Malignancies Players by Market Size
  3.1.1 Global Top Hematologic Malignancies Players by Revenue (2015-2020)
  3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2015-2020)
  3.1.3 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hematologic Malignancies Market Concentration Ratio
  3.2.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2019
3.3 Hematologic Malignancies Key Players Head office and Area Served
3.4 Key Players Hematologic Malignancies Product Solution and Service
3.5 Date of Enter into Hematologic Malignancies Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Hematologic Malignancies Historic Market Size by Type (2015-2020)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2021-2026)

5 HEMATOLOGIC MALIGNANCIES BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Hematologic Malignancies Market Size by Application (2015-2020)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Hematologic Malignancies Market Size (2015-2020)
6.2 Hematologic Malignancies Key Players in North America (2019-2020)
6.3 North America Hematologic Malignancies Market Size by Type (2015-2020)
6.4 North America Hematologic Malignancies Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Hematologic Malignancies Market Size (2015-2020)
7.2 Hematologic Malignancies Key Players in Europe (2019-2020)
7.3 Europe Hematologic Malignancies Market Size by Type (2015-2020)
7.4 Europe Hematologic Malignancies Market Size by Application (2015-2020)

8 CHINA

8.1 China Hematologic Malignancies Market Size (2015-2020)
8.2 Hematologic Malignancies Key Players in China (2019-2020)
8.3 China Hematologic Malignancies Market Size by Type (2015-2020)
8.4 China Hematologic Malignancies Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Hematologic Malignancies Market Size (2015-2020)
9.2 Hematologic Malignancies Key Players in Japan (2019-2020)
9.3 Japan Hematologic Malignancies Market Size by Type (2015-2020)
9.4 Japan Hematologic Malignancies Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Hematologic Malignancies Market Size (2015-2020)
10.2 Hematologic Malignancies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020)
10.4 Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020)

11 INDIA

11.1 India Hematologic Malignancies Market Size (2015-2020)
11.2 Hematologic Malignancies Key Players in India (2019-2020)
11.3 India Hematologic Malignancies Market Size by Type (2015-2020)
11.4 India Hematologic Malignancies Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Hematologic Malignancies Market Size (2015-2020)
12.2 Hematologic Malignancies Key Players in Central & South America (2019-2020)
12.3 Central & South America Hematologic Malignancies Market Size by Type (2015-2020)
12.4 Central & South America Hematologic Malignancies Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer, Inc.
  13.1.1 Pfizer, Inc. Company Details
  13.1.2 Pfizer, Inc. Business Overview and Its Total Revenue
  13.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
  13.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020))
  13.1.5 Pfizer, Inc. Recent Development
13.2 F. Hoffmann-LA Roche ltd
  13.2.1 F. Hoffmann-LA Roche ltd Company Details
  13.2.2 F. Hoffmann-LA Roche ltd Business Overview and Its Total Revenue
  13.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
  13.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020)
  13.2.5 F. Hoffmann-LA Roche ltd Recent Development
13.3 Sanofi-Aventis
  13.3.1 Sanofi-Aventis Company Details
  13.3.2 Sanofi-Aventis Business Overview and Its Total Revenue
  13.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
  13.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020)
  13.3.5 Sanofi-Aventis Recent Development
13.4 Bristol-Myers Squibb Company
  13.4.1 Bristol-Myers Squibb Company Company Details
  13.4.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
  13.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
  13.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020)
  13.4.5 Bristol-Myers Squibb Company Recent Development
13.5 AbbVie, Inc.
  13.5.1 AbbVie, Inc. Company Details
  13.5.2 AbbVie, Inc. Business Overview and Its Total Revenue
  13.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
  13.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
  13.5.5 AbbVie, Inc. Recent Development
13.6 Novartis AG
  13.6.1 Novartis AG Company Details
  13.6.2 Novartis AG Business Overview and Its Total Revenue
  13.6.3 Novartis AG Hematologic Malignancies Introduction
  13.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2015-2020)
  13.6.5 Novartis AG Recent Development
13.7 GlaxoSmithKline PLC
  13.7.1 GlaxoSmithKline PLC Company Details
  13.7.2 GlaxoSmithKline PLC Business Overview and Its Total Revenue
  13.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
  13.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020)
  13.7.5 GlaxoSmithKline PLC Recent Development
13.8 Celgene Corporation
  13.8.1 Celgene Corporation Company Details
  13.8.2 Celgene Corporation Business Overview and Its Total Revenue
  13.8.3 Celgene Corporation Hematologic Malignancies Introduction
  13.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020)
  13.8.5 Celgene Corporation Recent Development
13.9 Johnson & Johnson Services, Inc.
  13.9.1 Johnson & Johnson Services, Inc. Company Details
  13.9.2 Johnson & Johnson Services, Inc. Business Overview and Its Total Revenue
  13.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
  13.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
  13.9.5 Johnson & Johnson Services, Inc. Recent Development
13.10 Takeda Pharmaceutical Company limited
  13.10.1 Takeda Pharmaceutical Company limited Company Details
  13.10.2 Takeda Pharmaceutical Company limited Business Overview and Its Total Revenue
  13.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Introduction
  13.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020)
  13.10.5 Takeda Pharmaceutical Company limited Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Hematologic Malignancies Key Market Segments
Table 2. Key Players Covered: Ranking by Hematologic Malignancies Revenue
Table 3. Ranking of Global Top Hematologic Malignancies Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hematologic Malignancies Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Leukemia
Table 6. Key Players of Lymphoma
Table 7. Key Players of Multiple Myeloma
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Hematologic Malignancies Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Hematologic Malignancies Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Hematologic Malignancies Players to Combat Covid-19 Impact
Table 14. Global Hematologic Malignancies Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Hematologic Malignancies Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Hematologic Malignancies Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Hematologic Malignancies Market Share by Regions (2015-2020)
Table 18. Global Hematologic Malignancies Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Hematologic Malignancies Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Hematologic Malignancies Market Growth Strategy
Table 24. Main Points Interviewed from Key Hematologic Malignancies Players
Table 25. Global Hematologic Malignancies Revenue by Players (2015-2020) (Million US$)
Table 26. Global Hematologic Malignancies Market Share by Players (2015-2020)
Table 27. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2019)
Table 28. Global Hematologic Malignancies by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Hematologic Malignancies Product Solution and Service
Table 31. Date of Enter into Hematologic Malignancies Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 34. Global Hematologic Malignancies Market Size Share by Type (2015-2020)
Table 35. Global Hematologic Malignancies Revenue Market Share by Type (2021-2026)
Table 36. Global Hematologic Malignancies Market Size Share by Application (2015-2020)
Table 37. Global Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 38. Global Hematologic Malignancies Market Size Share by Application (2021-2026)
Table 39. North America Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Hematologic Malignancies Market Share (2019-2020)
Table 41. North America Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 42. North America Hematologic Malignancies Market Share by Type (2015-2020)
Table 43. North America Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 44. North America Hematologic Malignancies Market Share by Application (2015-2020)
Table 45. Europe Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Hematologic Malignancies Market Share (2019-2020)
Table 47. Europe Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Hematologic Malignancies Market Share by Type (2015-2020)
Table 49. Europe Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Hematologic Malignancies Market Share by Application (2015-2020)
Table 51. China Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 52. China Key Players Hematologic Malignancies Market Share (2019-2020)
Table 53. China Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 54. China Hematologic Malignancies Market Share by Type (2015-2020)
Table 55. China Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 56. China Hematologic Malignancies Market Share by Application (2015-2020)
Table 57. Japan Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Hematologic Malignancies Market Share (2019-2020)
Table 59. Japan Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Hematologic Malignancies Market Share by Type (2015-2020)
Table 61. Japan Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Hematologic Malignancies Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Hematologic Malignancies Market Share (2019-2020)
Table 65. Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Hematologic Malignancies Market Share by Type (2015-2020)
Table 67. Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Hematologic Malignancies Market Share by Application (2015-2020)
Table 69. India Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 70. India Key Players Hematologic Malignancies Market Share (2019-2020)
Table 71. India Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 72. India Hematologic Malignancies Market Share by Type (2015-2020)
Table 73. India Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 74. India Hematologic Malignancies Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Hematologic Malignancies Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Hematologic Malignancies Market Share (2019-2020)
Table 77. Central & South America Hematologic Malignancies Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Hematologic Malignancies Market Share by Type (2015-2020)
Table 79. Central & South America Hematologic Malignancies Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Hematologic Malignancies Market Share by Application (2015-2020)
Table 81. Pfizer, Inc. Company Details
Table 82. Pfizer, Inc. Business Overview
Table 83. Pfizer, Inc. Product
Table 84. Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 85. Pfizer, Inc. Recent Development
Table 86. F. Hoffmann-LA Roche ltd Company Details
Table 87. F. Hoffmann-LA Roche ltd Business Overview
Table 88. F. Hoffmann-LA Roche ltd Product
Table 89. F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 90. F. Hoffmann-LA Roche ltd Recent Development
Table 91. Sanofi-Aventis Company Details
Table 92. Sanofi-Aventis Business Overview
Table 93. Sanofi-Aventis Product
Table 94. Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 95. Sanofi-Aventis Recent Development
Table 96. Bristol-Myers Squibb Company Company Details
Table 97. Bristol-Myers Squibb Company Business Overview
Table 98. Bristol-Myers Squibb Company Product
Table 99. Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 100. Bristol-Myers Squibb Company Recent Development
Table 101. AbbVie, Inc. Company Details
Table 102. AbbVie, Inc. Business Overview
Table 103. AbbVie, Inc. Product
Table 104. AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 105. AbbVie, Inc. Recent Development
Table 106. Novartis AG Company Details
Table 107. Novartis AG Business Overview
Table 108. Novartis AG Product
Table 109. Novartis AG Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 110. Novartis AG Recent Development
Table 111. GlaxoSmithKline PLC Company Details
Table 112. GlaxoSmithKline PLC Business Overview
Table 113. GlaxoSmithKline PLC Product
Table 114. GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 115. GlaxoSmithKline PLC Recent Development
Table 116. Celgene Corporation Business Overview
Table 117. Celgene Corporation Product
Table 118. Celgene Corporation Company Details
Table 119. Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 120. Celgene Corporation Recent Development
Table 121. Johnson & Johnson Services, Inc. Company Details
Table 122. Johnson & Johnson Services, Inc. Business Overview
Table 123. Johnson & Johnson Services, Inc. Product
Table 124. Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 125. Johnson & Johnson Services, Inc. Recent Development
Table 126. Takeda Pharmaceutical Company limited Company Details
Table 127. Takeda Pharmaceutical Company limited Business Overview
Table 128. Takeda Pharmaceutical Company limited Product
Table 129. Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020) (Million US$)
Table 130. Takeda Pharmaceutical Company limited Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Hematologic Malignancies Market Share by Type: 2020 VS 2026
Figure 2. Leukemia Features
Figure 3. Lymphoma Features
Figure 4. Multiple Myeloma Features
Figure 5. Others Features
Figure 6. Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
Figure 7. Chemotherapy Case Studies
Figure 8. Radiotherapy Case Studies
Figure 9. Immunotherapy Case Studies
Figure 10. Stem Cell Transplantation Case Studies
Figure 11. Others Case Studies
Figure 12. Hematologic Malignancies Report Years Considered
Figure 13. Global Hematologic Malignancies Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Hematologic Malignancies Market Share by Regions: 2020 VS 2026
Figure 15. Global Hematologic Malignancies Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Hematologic Malignancies Market Share by Players in 2019
Figure 18. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Hematologic Malignancies Revenue in 2019
Figure 20. North America Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Hematologic Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Pfizer, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Pfizer, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 29. F. Hoffmann-LA Roche ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. F. Hoffmann-LA Roche ltd Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 31. Sanofi-Aventis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Sanofi-Aventis Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 33. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Bristol-Myers Squibb Company Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 35. AbbVie, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. AbbVie, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 37. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Novartis AG Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 39. GlaxoSmithKline PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. GlaxoSmithKline PLC Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 41. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Celgene Corporation Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 43. Johnson & Johnson Services, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Johnson & Johnson Services, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 45. Takeda Pharmaceutical Company limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Takeda Pharmaceutical Company limited Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed